Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,910,000 shares, an increase of 18.1% from the September 30th total of 3,310,000 shares. Currently, 17.8% of the shares of the stock are short sold. Based on an average daily volume of 569,300 shares, the days-to-cover ratio is currently 6.9 days.
A number of brokerages have recently issued reports on ADMS. Evercore ISI reissued a “buy” rating and issued a $55.00 price objective on shares of Adamas Pharmaceuticals in a research note on Monday, August 12th. Northland Securities restated a “buy” rating and set a $15.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, November 8th. Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. JMP Securities decreased their price target on Adamas Pharmaceuticals to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Finally, Cowen set a $5.00 price objective on Adamas Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Hold” and an average price target of $16.73.
Large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in Adamas Pharmaceuticals by 8.7% in the 3rd quarter. Rhumbline Advisers now owns 37,166 shares of the specialty pharmaceutical company’s stock worth $190,000 after acquiring an additional 2,974 shares during the last quarter. Advisor Group Inc. raised its stake in Adamas Pharmaceuticals by 53.4% during the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 3,900 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in Adamas Pharmaceuticals during the second quarter valued at $25,000. Charles Schwab Investment Management Inc. lifted its position in Adamas Pharmaceuticals by 10.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 46,928 shares of the specialty pharmaceutical company’s stock valued at $291,000 after purchasing an additional 4,381 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Adamas Pharmaceuticals by 63.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 6,000 shares during the last quarter. Institutional investors own 51.99% of the company’s stock.
Shares of NASDAQ:ADMS traded down $0.05 during midday trading on Friday, reaching $6.47. 485,949 shares of the company were exchanged, compared to its average volume of 484,639. The company has a current ratio of 6.35, a quick ratio of 6.15 and a debt-to-equity ratio of 6.72. The stock has a market cap of $181.36 million, a PE ratio of -1.33 and a beta of 1.77. The business’s fifty day moving average is $4.95 and its two-hundred day moving average is $5.48. Adamas Pharmaceuticals has a one year low of $3.35 and a one year high of $12.57.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.09). Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. The company had revenue of $13.93 million during the quarter, compared to analysts’ expectations of $14.36 million. As a group, sell-side analysts expect that Adamas Pharmaceuticals will post -3.92 EPS for the current year.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Featured Article: Do You Need a Fiduciary?
Receive News & Ratings for Adamas Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.